Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) have been assigned a consensus rating of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $3.75.

A number of analysts recently commented on the company. Wall Street Zen cut Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th.

Werewolf Therapeutics Trading Up 5.8%

Werewolf Therapeutics stock opened at $0.49 on Thursday. The stock has a market cap of $23.81 million, a PE ratio of -0.40 and a beta of 0.41. The stock has a 50-day moving average price of $0.76 and a 200 day moving average price of $0.76. Werewolf Therapeutics has a 52 week low of $0.40 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, equities analysts predict that Werewolf Therapeutics will post -1.29 EPS for the current year.

Insider Activity

In other news, Director Luke Evnin sold 305,741 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70. Following the transaction, the director directly owned 1,273,008 shares in the company, valued at $891,105.60. This represents a 19.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 376,526 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $0.71, for a total transaction of $267,333.46. Following the transaction, the insider owned 418,813 shares in the company, valued at approximately $297,357.23. The trade was a 47.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 1,916,663 shares of company stock worth $1,250,874. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Regal Investment Advisors LLC lifted its holdings in shares of Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares during the period. Vontobel Holding Ltd. lifted its holdings in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter worth about $48,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics during the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC lifted its holdings in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after acquiring an additional 62,414 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.